Literature DB >> 8899485

Clinical assessment of trough levels for monitoring of rejection in cyclosporine-treated kidney transplant recipients.

S Takahara1, M Namiki, Y Kokado, H Kameoka, A Okuyama.   

Abstract

We evaluated whether trough cyclosporine (CYA) level monitoring was useful in the diagnosis of rejection within 2 weeks after transplantation. Rejection occurred in 14 out of 17 patients (82.3%) treated with CYA, mizoribine (MZR) and prednisolone (Pred) when trough CYA levels dropped below 70 ng/ml, suggesting the importance of trough level monitoring. When anti-lymphocyte globulin (ALG) was added to the 3 above-mentioned drugs, however, rejection occurred in only 1 patient (6.7%) and 2 patients (13.3%), respectively, within 1 week and 1-2 weeks after transplantation, suggesting that trough level monitoring is less important in patients treated with these 4 drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8899485     DOI: 10.1007/bf02550507

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  4 in total

1.  Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group.

Authors: 
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

2.  Combined immunosuppression with low-dose cyclosporine, mizoribine, and prednisolone.

Authors:  S Takahara; T Fukunishi; Y Kokado; Y Ichikawa; M Ishibashi; S Nagano; T Sonoda
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

3.  Area-under-the-curve monitoring of cyclosporine therapy: performance of different assay methods and their target concentrations.

Authors:  J Grevel; K L Napoli; S Gibbons; B D Kahan
Journal:  Ther Drug Monit       Date:  1990-01       Impact factor: 3.681

4.  Cyclosporin A in patients receiving renal allografts from cadaver donors.

Authors:  R Y Calne; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; B D Pentlow; K Rolles
Journal:  Lancet       Date:  1978 Dec 23-30       Impact factor: 79.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.